A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates
Johnston, Tom; Millar, Zak A; Huot, Philippe; Wagg, Keith; Theile, Sherri; Salomonczyk, Danielle; Yong-Kee, Christopher J; Gandy, Michael N; McIldowie, Matthew; Lewis, Katie; Gomez-Ramirez, Jordie; Lee, Joohyung; Fox, Susan H; Martin-Iverson, Mathew; Nash, Joanne E; Piggott, Matthew J; Brotchie, Jonathan M
Treatment of Parkinson's disease with dopaminergic agents, such as L-DOPA, is frequently compromised by disabling side effects, particularly dyskinesia and a shortening in duration of antiparkinsonian action. Studies in animal models and anecdotal evidence from a patient with Parkinson's disease show that the illicit drug ecstasy (MDMA) can alleviate these side effects, though with many drawbacks (e.g., psychoactivity). MDMA itself thus has little therapeutic potential. On the basis of known...[Show more]
|Collections||ANU Research Publications|
|01_Johnston_A_novel_MDMA_analogue,_2012.pdf||565.83 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.